Last reviewed · How we verify

NCT05386134

Adaptive Optics Retinal Imaging in Inherited and Acquired Retinal Disorders

Recruiting now Last updated 10 January 2025
What this trial tests

trial testing Adaptive Optics Retinal Camera in Genetic Disease in 200 participants. Currently enrolling.

Timeline
13 June 2022
Primary endpoint
13 June 2032
13 June 2033

Quick facts

Lead sponsorThe Hospital for Sick Children
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment200
Start date13 June 2022
Primary completion13 June 2032
Estimated completion13 June 2033
Sites1 location across Canada

Drugs / interventions tested

Conditions studied

Sponsor

The Hospital for Sick Children

Who can join

Adults 5 to 70, any sex, with Genetic Disease or Inherited Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Prospective Observational study. The aim of the study is to understand the underlying photoreceptor, retinal pigment epithelium or retinal vascular aberrations in inherited and acquired retinal disorders. The study would use adaptive optics (AO) technology to assist in-vivo visualization of these retinal structures and ascertain changes from normal. Further, by using the AO imaging in patients before and after treatments, this study aims to better understand the effect of various interventions and develop AO as an outcome measure in various retinal disorders.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Genetic Disease

Currently open trials in the same condition.

Other The Hospital for Sick Children trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05386134.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing